Nutra Pharma is providing updates on their work in improving manufacturing scale and capabilities for new product launches for their OTC drugs and potential dietary supplements
Plantation, Florida, March 17, 2022 — McapMediaWire — Nutra Pharma Corporation (OTC Pink: NPHC), a biotechnology company marketing Nyloxin®, Pet Pain-Away
, Luxury Feet and Equine Pain-Away in the over-the-counter (OTC) pain management market and which is also developing treatments for Multiple Sclerosis (MS), Human Immunodeficiency Virus (HIV) and Pain, is providing updates today on increasing their manufacturing capabilities for the production of their own products as well as third party companies with OTC drugs as well as dietary supplements.
“Last year, we announced that we were bringing all of our manufacturing in-house,” stated Brent Bonner, Warehouse Manager of Nutra Pharma. “At that time, we added a full liquid filling line that included automatic filling, capping, coding, labeling and heat shrinking for most of our products,” he continued. “Over the last few months, we have continued to expand our manufacturing capabilities. We’ve added a tube-filling line that we use for Pet Pain-Away. This equipment can also be used for future gel products that may include a personal care line. We’ve also added a capsule-filling machine as well as an extrusion line that we will use for product extensions, new product launches and contract manufacturing for the production of dietary supplements,” he concluded.
In addition to Amazon, Walmart Marketplace and the Company’s own product websites; Nutra Pharma announced previously their plans to greatly expand online marketing and promotional activity. The company has also previously announced plans for broader retail distribution of their OTC products for the treatment of pain.
“Expanding our in-house manufacturing capabilities has put Nutra Pharma in a very good position as far as reduced product costs, higher margins, faster product upgrades and an increased ability to launch new and innovative products,” commented Rik J Deitsch, CEO of Nutra Pharma. “We are also well positioned to act as a contract manufacturer for other companies as they launch OTC drugs or dietary supplements,” he continued. “The COVID crisis and subsequent supply chain issues caused by the global shutdown has shined a light on the need to bring manufacturing back to America. We are proud to increase our own product line; potentially formulate and make products for contract customers as well as provide future manufacturing jobs as Nutra Pharma moves forward with these projects,” he concluded.
Nutra Pharma will provide further updates on new products, manufacturing capabilities and contract manufacturing opportunities throughout the rest of 2022.
About Nutra Pharma Corp.
Nutra Pharma Corporation operates as a biotechnology company specializing in the acquisition, licensing, and commercialization of pharmaceutical products and technologies for the management of neurological disorders, cancer, autoimmune, and infectious diseases, including Multiple Sclerosis (MS), Human Immunodeficiency Virus (HIV) and Pain. Additionally, the Company markets drug products for sale for the treatment of pain under the brand Nyloxin®, Equine Pain-Away, Luxury Feet and Pet Pain-Away. For additional information about Nutra Pharma, visit:
http://www.NutraPharma.com or
http://www.nyloxin.com
http://www.petpainaway.com
http://www.equinepainaway.com
http://www.luxuryfeet.com
SEC Disclaimer
This press release contains forward-looking statements. The words or phrases “would be,” “will allow,” “intends to,” “will likely result,” “are expected to,” “will continue,” “is anticipated,” “estimate,” “project,” or similar expressions are intended to identify “forward-looking statements.” Actual results could differ materially from those projected in Nutra Pharma’s (“the Company”) business plan. The expansion of manufacturing should not be construed as an indication in any way whatsoever of the future value of the Company’s common stock or its financial value. The Company’s filings may be accessed at the SEC’s Edgar system at www.sec.gov. Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date. The Company cautions readers not to place reliance on such statements. Unless otherwise required by applicable law, we do not undertake, and we specifically disclaim any obligation, to update any forward-looking statements to reflect occurrences, developments, unanticipated events or circumstances after the date of such statement.
| Contact: |
| Nutra Pharma Corp. Nina Goldstein 877-895-5647 IR@nutrapharma.com |
